AngioDynamics (NASDAQ:ANGO) Lowered to C at TheStreet

TheStreet lowered shares of AngioDynamics (NASDAQ:ANGO) from a b rating to a c rating in a report released on Monday, July 29th, TheStreetRatingsTable reports.

Several other equities analysts also recently commented on the company. ValuEngine upgraded AngioDynamics from a hold rating to a buy rating in a research note on Tuesday, July 2nd. Zacks Investment Research upgraded AngioDynamics from a sell rating to a hold rating and set a $20.00 price objective on the stock in a research note on Tuesday, June 4th. Finally, BidaskClub downgraded AngioDynamics from a buy rating to a hold rating in a research note on Tuesday, July 30th. Three equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $21.50.

ANGO traded down $0.28 during midday trading on Monday, reaching $18.68. 67,968 shares of the company were exchanged, compared to its average volume of 216,306. AngioDynamics has a one year low of $18.11 and a one year high of $25.48. The company’s fifty day moving average price is $20.36 and its 200 day moving average price is $20.89. The company has a market cap of $696.33 million, a price-to-earnings ratio of 22.51 and a beta of 0.66. The company has a debt-to-equity ratio of 0.20, a quick ratio of 3.75 and a current ratio of 4.30.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, July 10th. The medical instruments supplier reported $0.25 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). AngioDynamics had a return on equity of 5.58% and a net margin of 17.06%. The business had revenue of $96.30 million during the quarter, compared to analysts’ expectations of $92.34 million. During the same quarter in the previous year, the firm earned $0.20 EPS. AngioDynamics’s quarterly revenue was up 9.1% on a year-over-year basis. As a group, sell-side analysts anticipate that AngioDynamics will post 0.27 earnings per share for the current fiscal year.

In other news, Director Kevin J. Gould sold 13,650 shares of the company’s stock in a transaction on Tuesday, July 16th. The shares were sold at an average price of $21.45, for a total value of $292,792.50. Following the transaction, the director now owns 61,774 shares of the company’s stock, valued at $1,325,052.30. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 2.80% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ANGO. Victory Capital Management Inc. increased its stake in AngioDynamics by 40.5% in the second quarter. Victory Capital Management Inc. now owns 3,773,543 shares of the medical instruments supplier’s stock valued at $74,301,000 after acquiring an additional 1,086,847 shares during the last quarter. Systematic Financial Management LP increased its stake in AngioDynamics by 586.4% in the second quarter. Systematic Financial Management LP now owns 380,622 shares of the medical instruments supplier’s stock valued at $7,494,000 after acquiring an additional 325,172 shares during the last quarter. Nuveen Asset Management LLC bought a new position in AngioDynamics in the second quarter valued at $4,865,000. Tributary Capital Management LLC grew its stake in shares of AngioDynamics by 39.9% during the first quarter. Tributary Capital Management LLC now owns 704,499 shares of the medical instruments supplier’s stock valued at $16,105,000 after buying an additional 200,829 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of AngioDynamics by 27.1% during the second quarter. Price T Rowe Associates Inc. MD now owns 607,751 shares of the medical instruments supplier’s stock valued at $11,967,000 after buying an additional 129,497 shares during the last quarter. 96.54% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Further Reading: What is operating income?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.